Clinical trial
A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage…
NCT00319917 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00319917 |
|---|---|
| Title | A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients |
| Official title | FK506 Phase 4 Study: A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | tacrolimus, placebo |
| Enrollment | 123 |
| Start date | Apr 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Apr 27, 2006 |
| Last update posted | Aug 21, 2014 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: